Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials
Faı̈ez Zannad, Christopher M. O’Connor, Javed Butler, Ciaran J. McMullan et autres
BACKGROUND: Following completion of the VICTORIA trial, vericiguat was approved for the treatment of worsening heart failure with reduced ejection fraction (HFrEF) and received a class IIb recommendation in European and North American guidelines. The subsequent VICTOR trial evaluated the use of …
fr, us, ch, ca, sg, pl, it, de, nl (code pays fourni par la source)
45 citations
The Lancet